DaVita stock has November 4, 2026 earnings date

Published on 10/17/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market value was USD 12.0 billion on October 16, 2026. DaVita stock closed at USD 187.31 on October 16, 2026, down 0.98 percent on NYSE.

Calendar and valuation points

DaVita is scheduled to report quarterly results on November 4, 2026.
Market capitalization stood at USD 12.0 billion on October 16, 2026.
DaVita stock closed at USD 187.31 at 4:00 p.m. ET on October 16, 2026, down 0.98 percent on the NYSE.
DaVita traded at a price to earnings ratio of 16.46 on October 16, 2026.

NYSE Trading Floor mit Händlern, digitalen Kursanzeigetafeln und Healthcare-Sektorcharts — NYSE-Handelsparkett mit Healthcare-Sektorcharts, DVA-Ticker und aktiven Händlern im Börsen-Editorial zu DaVita Inc. US23918K1088, Illustration mit AI erstellt.

DaVita Inc. is scheduled to report its next quarterly results on November 4, 2026. The company closed at USD 187.31 at 4:00 p.m. ET on October 16, 2026, down 0.98 percent on the NYSE.

November date sets the calendar

The November 4 reporting date gives investors the next fixed point for evaluating treatment volumes, reimbursement trends and operating costs. MetaCap identifies November 4, 2026 as DaVita's next earnings date and says the company is expected to report results for the period ended September 2026.

The scheduled release follows DaVita's second-quarter reporting period, which ended June 30, 2026. Investors will therefore have a fresh operating update before the end of the fourth quarter, with the November report likely to frame expectations for the remainder of the fiscal year.

Market value and earnings expectations

DaVita's market capitalization was USD 12.0 billion on October 16, 2026. The stock traded at a price to earnings ratio of 16.46 and carried no trailing dividend yield in the same market snapshot.

The valuation sits between the two healthcare names used for comparison below. Fresenius Medical Care had a lower price to earnings ratio, while U.S. Physical Therapy carried a much higher multiple. That spread makes the November results particularly relevant for judging whether DaVita's earnings base supports its current valuation.

Trading range and yearly context

DaVita's 52-week range extended from USD 101.00 to USD 247.49. The October 16 close was USD 60.18 below the high, equivalent to 24.32 percent, and USD 86.31 above the low, or 85.45 percent.

Trading volume reached 505,263 shares against an average volume of 755,129 shares on October 16, 2026. The session therefore finished below the recent average in activity as well as lower on the day.

Comparison with peers

DaVita Inc. (NYSE, USD): minus 0.98 percent, P/E 16.46, market capitalization USD 12.0 billion

Fresenius Medical Care (NYSE, USD): plus 0.18 percent, P/E 11.91, market capitalization USD 11.8 billion

U.S. Physical Therapy (NYSE, USD): minus 0.31 percent, P/E 504.18, market capitalization USD 1.3 billion

Valuation and upcoming date

The next scheduled date remains the clearest near-term calendar marker. A price to earnings ratio of 16.46 places DaVita below U.S. Physical Therapy's 504.18 and above Fresenius Medical Care's 11.91, while the three companies showed different daily changes on October 16, 2026.